HOME >> BIOLOGY >> NEWS
Burnham to collaborate on NCI-funded task force to find 'molecular signature' for prostate cancer

(La Jolla, CA December 13, 2005) The Burnham Institute for Medical Research will collaborate on a multi-disciplinary, multi-institutional task force aimed at defining the "molecular signatures" that distinguish different stages of prostate cancer funded by the National Cancer Institute as part of its new Strategic Partnering to Evaluate Cancer Signatures ("SPECS") Program. Led by UC Irvine, the consortium will receive $9.5 MM over the next five years.

One out of six men in America will be afflicted with prostate cancer over the course of a lifetime; one-third by age 50, and nearly 75% by age 75. According to the National Cancer Institute, about half of the 16% diagnosed for prostate cancer will develop significant symptoms. In the other half, prostate tumors develop so slowly that the disease will not progress fully in the bearer's lifetime. Current diagnostic methods for prostate cancer cannot distinguish between the rapid-growing, life-threatening and the slow-growing, indolent forms of the disease. Physicians must prescribe treatment with partial knowledge, in many cases recommending treatment that is unnecessary. The SPECS Program consortium aims to examine the various phases of prostate cancer, profiling the disease from its genetic make up, developing a molecular signature, which ultimately will enable better-informed diagnoses and treatment.

Drs. John C. Reed, Stanislaw Krajewski, and Maryla Krajewska of the Burnham will conduct tissue microarray analysis examining 4,000 prostate tissue samples for cancer "markers" or certain gene products that are indicative of the clinical behavior of prostate cancer cells.

"These comparative analyses will be compiled into a diagnostic tool that will guide a more informed prognosis for individuals diagnosed with prostate cancer," said Dr. Reed. "Working together with the SPECS team, we look forward to defining the molecular signatures that identify which prostate cancers require therapy, and
'"/>

Contact: Nancy Beddingfield
nbeddingfield@burnham.org
858-646-3146
Burnham Institute
14-Dec-2005


Page: 1 2

Related biology news :

1. NIH awards $7.39 million to Burnham neurobiologists
2. CIRM awards $6M to Burnham Institute
3. CIRM awards $5.9 million to Burnham Institute
4. Burnham Institute for Medical Research announces affiliation with UC Santa Barbara
5. Burnham awarded $12.7 million from NIH to create one of nations top neuroscience research centers
6. Burnham Institute for Medical Research & UC San Diego establish Joint Center for Molecular Modeling
7. Burnham Institute to collaborate in NCI funded Center of Cancer Nanotechnology Excellence
8. NFCR - Prostate Cancer Foundation unite with Burnham Institute to expedite cancer drug discovery
9. NIH selects Burnham Institute for Exploratory Center for Human Embryonic Stem Cell Research
10. Anthrax inhibitors identified by Burnham team
11. NIH awards $11.9 M to The Burnham Institute to establish the San Diego Chemical Screening Center

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 09, 2020 , ... Today CJ BIO announced the first in a series ... “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across ... Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the ...
(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the solution ... history of eSource, the reasons it did not take off as quickly as people ... the industry is moving towards capturing data electronically for clinical trials and then repurposing ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said ... on the market and we were pleased that the IFT jury recognized that.” reFRESH™ ... creating a natural way to extend the shelf life and improve the safety of ...
(Date:7/10/2020)... ... July 09, 2020 , ... In most ... used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate ... Dr MA has been using the zebrafish model to investigate the causes of ...
(Date:7/1/2020)... , ... June 29, 2020 , ... ... to competitively procured purchasing contracts to its membership, recently named BioFit Engineered ... members with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and ...
Breaking Biology Technology:
Cached News: